India, Jan. 6 -- image credit- freepik

France-basedValneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

Valneva's strategic intent in regaining full rights is to assume direct control over its supply chain and commercialisation for endemic high-risk countries, thereby accelerating access for regions most affected by the disease.

Supportingaccess to the vaccine in low-and-middle-income countries (LMICs)fallswithin the framework of thefundingagreementValnevasigned withthe Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024with co-funding from the European Unio...